Ardian in talks to buy Bio 7 from Chequers Capital


arc deArdian is in exclusive talks to buy a minority stake in the clinical pathology laboratories operator Bio 7 group from fellow private equity firm Chequers Capital.

The group operates 56 point-of –care laboratories and three main technical platforms in Essonne, Seine et Marne and Yvelines in France.

Chequers bought a stake in Bio 7 alongside the founders and management team in 2009.

The company expects to report revenues of over €55m this year, which it said would represent a “sharp increase” from 2013.

Ardian managing director François Jerphagnon said, “We would be delighted to acquire a stake in the Bio 7 group.
“The group is a leader in its market and benefits from teams with renowned scientific expertise.

“We hope to continue the group’s development, through both organic growth and acquisitions, working closely with the management team.”

Copyright © 2014 AltAssets